GSK Stock Analysis: Buy, Sell, or Hold?
GSK - GSK plc American Depositary Shares (Each representing two Ordinary Shares)
$51.51
-0.18 (-0.35%)
▼
5d:
-0.9%
30d:
-4.01%
90d:
-0.19%
BUY
HIGH Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Jul 28, 2026
0d
Get Alerted When GSK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: GSK shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: GSK shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$72.31
Based on 6.1% avg growth
INTRINSIC VALUE TODAY
$44.90
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GSK is currently trading at $51.51, which is considered slightly low relative to its 30-day fair value range of $51.15 to $53.01. The stock's valuation (Forward PE: 10.0) is in line with its historical norms (10.5). Remarkably, the market is currently pricing in an annual earnings decline of 1.4% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, GSK is in a downtrend. Immediate support is located at $49.89, while resistance sits at $55.78.
Market Sentiment: GSK has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $58.08 (+12.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, GSK is in a downtrend. Immediate support is located at $49.89, while resistance sits at $55.78.
Market Sentiment: GSK has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $58.08 (+12.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$51.15 -
$53.01
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
88.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($58.08)
Trading Range Analysis
30-Day Trading Range
$51.15 -
$53.01
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$49.89
Resistance Level
$55.79
Current Trend
Downtrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.03
Wall Street Target
$58.08
(+12.7%)
Revenue Growth (YoY)
5.3%
Earnings Growth (YoY)
-69.5%
Profit Margin
14.5%
Valuation Discount vs History
-1.4% cheaper
PE vs Historical
10.0 vs 10.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.4%
(market-implied from PE analysis)
1-Year Target
$50.79
(-1%)
2-Year Target
$50.08
(-3%)
3-Year Target
$49.38
(-4%)
3-Yr Target (if PE normalizes)
(PE: 10→11)
$51.70
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.7, Growth: 8.1%)
$134.67
(+161%)
Base:
(SPY PE: 10.0, Growth: 8.1%)
$65.15
(+27%)
Bear:
(PE: 8.5, Growth: 8.1%)
$55.38
(+8%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (16x PE), but valuation improves significantly next year (10x PE) as earnings recover.
Trailing PE: 16.41 | Current EPS (TTM): $3.15
Bull Case
$92.71
(+80%)
Analyst growth 63.1%, PE expands to 18.1
Base Case
$84.29
(+64%)
Market implied 63.1%, PE stable at 16.4
Bear Case
$35.15
(-32%)
Severe decline -20.0%, PE contracts to 14.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 10.0 to 10.5
Stabilization Target:
$53.93
(+4.7%)
PE Expansion Potential:
+4.7%
Share & Embed Analysis
Last updated: August 03, 2026 7:11 PM ET
Data refreshes hourly during market hours. Next update: 8:11 PM
Data refreshes hourly during market hours. Next update: 8:11 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GSK showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1277 | 49 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$157 | 54 HOLD |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$357 | 56 HOLD |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$234 | 55 HOLD |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$270 | 52 HOLD |
